Keywords: patients, enter, pivotal, study, genmab, cll, drug

132 patients enter pivotal study of Genmab CLL drug

Article | 10 December 2007

Print This

Danish drugmaker Genmab AS has completed recruitment in a pivotal study of ofatumumab (HuMax-CD20) for the treatment of refractory chronic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in